文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

解析 1 型神经纤维瘤病相关神经纤维瘤中的杂合性丢失(LOH):拷贝数中性 LOH 的重要性。

Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH.

机构信息

Institut de Medicina Predictiva i Personalitzada del Càncer, Badalona, Barcelona, Spain.

出版信息

Hum Mutat. 2011 Jan;32(1):78-90. doi: 10.1002/humu.21387.


DOI:10.1002/humu.21387
PMID:21031597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3151547/
Abstract

Dermal neurofibromas (dNFs) are benign tumors of the peripheral nervous system typically associated with Neurofibromatosis type 1 (NF1) patients. Genes controlling the integrity of the DNA are likely to influence the number of neurofibromas developed because dNFs are caused by somatic mutational inactivation of the NF1 gene, frequently evidenced by loss of heterozygosity (LOH). We performed a comprehensive analysis of the prevalence and mechanisms of LOH in dNFs. Our study included 518 dNFs from 113 patients. LOH was detected in 25% of the dNFs (N = 129). The most frequent mechanism causing LOH was mitotic recombination, which was observed in 62% of LOH-tumors (N = 80), and which does not reduce the number of NF1 gene copies. All events were generated by a single crossover located between the centromere and the NF1 gene, resulting in isodisomy of 17q. LOH due to the loss of the NF1 gene accounted for a 38% of dNFs with LOH (N = 49), with deletions ranging in size from ∼80 kb to ∼8 Mb within 17q. In one tumor we identified the first example of a neurofibroma-associated second-hit type-2 NF1 deletion. Analysis of the prevalence of mechanisms causing LOH in dNFs in individual patients (possibly under genetic control) will elucidate whether there exist interindividual variation.

摘要

皮肤神经纤维瘤(dNFs)是周围神经系统的良性肿瘤,通常与神经纤维瘤病 1 型(NF1)患者相关。控制 DNA 完整性的基因可能会影响神经纤维瘤的数量,因为 dNFs 是由 NF1 基因的体细胞突变失活引起的,通常表现为杂合性丢失(LOH)。我们对 dNFs 中 LOH 的流行情况和机制进行了全面分析。我们的研究包括 113 名患者的 518 个 dNFs。25%的 dNFs 存在 LOH(N = 129)。导致 LOH 的最常见机制是有丝分裂重组,在 62%的 LOH 肿瘤中观察到(N = 80),这不会减少 NF1 基因拷贝数。所有事件都是由位于着丝粒和 NF1 基因之间的单一交叉产生的,导致 17q 的同二倍体。由于 NF1 基因的丢失导致的 LOH 占 LOH 的 dNFs 的 38%(N = 49),LOH 大小从 17q 内的 80kb 到 8Mb 不等。在一个肿瘤中,我们鉴定了首例与神经纤维瘤相关的第二打击型 2 NF1 缺失。分析单个患者(可能受遗传控制)中导致 LOH 的机制的流行情况将阐明是否存在个体间的差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/985ec841db85/humu0032-0078-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/aa467501ace8/humu0032-0078-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/2926c4534804/humu0032-0078-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/9a515b216c9e/humu0032-0078-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/3df0a564277f/humu0032-0078-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/985ec841db85/humu0032-0078-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/aa467501ace8/humu0032-0078-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/2926c4534804/humu0032-0078-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/9a515b216c9e/humu0032-0078-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/3df0a564277f/humu0032-0078-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa2a/3151547/985ec841db85/humu0032-0078-f5.jpg

相似文献

[1]
Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH.

Hum Mutat. 2011-1

[2]
Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.

J Invest Dermatol. 2009-3

[3]
Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.

Genes Chromosomes Cancer. 2000-8

[4]
Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations.

Hum Genet. 2001-5

[5]
Utilization of Whole-Exome Next-Generation Sequencing Variant Read Frequency for Detection of Lesion-Specific, Somatic Loss of Heterozygosity in a Neurofibromatosis Type 1 Cohort with Tibial Pseudarthrosis.

J Mol Diagn. 2017-5

[6]
Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.

Hum Mutat. 2004-2

[7]
Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene.

Biochem Biophys Res Commun. 1997-5-19

[8]
Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients.

Genes Chromosomes Cancer. 2006-10

[9]
Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1.

Am J Hum Genet. 2000-2

[10]
Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

Neurogenetics. 2010-4-1

引用本文的文献

[1]
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumors.

medRxiv. 2025-2-6

[2]
Adeno-associated viral vector targeted evolution for neurofibromatosis gene delivery.

Trends Mol Med. 2025-4

[3]
A Comprehensive Overview of NF1 Mutations in Iranian Patients.

Neuromolecular Med. 2024-7-2

[4]
A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.

Cell Rep Methods. 2024-5-20

[5]
Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.

JCI Insight. 2024-1-4

[6]
Genomic Mosaicism of the Brain: Origin, Impact, and Utility.

Neurosci Bull. 2024-6

[7]
Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.

J Invest Dermatol. 2023-8

[8]
Schwannomatosis patient who was followed up for fifteen years: A case report.

World J Clin Cases. 2022-7-16

[9]
Tumor and Constitutional Sequencing for Neurofibromatosis Type 1.

JCO Precis Oncol. 2022-5

[10]
Modeling Somatic Mutations Associated With Neurodevelopmental Disorders in Human Brain Organoids.

Front Mol Neurosci. 2022-1-4

本文引用的文献

[1]
Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

Neurogenetics. 2010-4-1

[2]
Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array.

Genes Chromosomes Cancer. 2009-10

[3]
Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.

Cell Stem Cell. 2009-5-8

[4]
Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1.

Hum Mol Genet. 2009-8-1

[5]
Comparative analysis of copy number variation in primate genomes.

Cytogenet Genome Res. 2008

[6]
The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas.

Neurogenetics. 2009-7

[7]
Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.

J Invest Dermatol. 2009-3

[8]
Germline and somatic NF1 gene mutations in plexiform neurofibromas.

Hum Mutat. 2008-8

[9]
SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples.

Am J Hum Genet. 2008-4

[10]
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.

Clin Cancer Res. 2008-2-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索